New combo aims to boost immunotherapy in elderly melanoma patients

NCT ID NCT07644897

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if the combination is safer and better tolerated than standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Thymosin alpha 1 and toripalimab (anti-PD-1 antibody)
What this could lead to: If it works, this combination could offer a safer, more effective treatment option for elderly patients with advanced melanoma who cannot tolerate standard therapies.
What could go wrong: This is a small, early-phase, single-arm trial with no control group, so results may not be conclusive. The combination may not improve outcomes and could still cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNE CHECKPOINT INHIBITOR IMMUNE-RELATED ADVERSE EVENT MELANOMA

Contacts and locations

Locations

Nanshan hospital
RECRUITING

Shenzhen, Guangdong, 518000, China
Sun yat-sen uniersity
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.